Related Resources for this page:
- Tumor Types
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Cancer Biomarkers
- Future Directions
- Antibody-Drug Conjugates
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Apoptosis
- Apoptotic pathways
- The Bcl-2 family
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- Resisting apoptosis
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- MAPK Signaling
- MEK Inhibitor (GDC-0973)
- Melanoma
- Multiple Myeloma
- Emerging therapeutic options
- PI3K Inhibitor (GDC-0941)
- Other Tumor Types
- Reactivating apoptosis
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Traditional Monoclonal Antibodies
- B-cell Surface Proteins
- Glossary
- Direct cell death
- Emerging therapeutic options
- Emerging therapeutic options
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Melanoma
- Emerging therapeutic options
- Obinutuzumab (GA101)
- Summary
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
Share
This figure was adapted with permission from Cell, Vol 100, Hanahan and Weinberg, The Hallmarks of Cancer, pp 57-70, Copyright Elsevier (2000).
Click here to view a larger version of this image
Evading apoptosis
This figure was adapted with permission from Cell, Vol 100, Hanahan and Weinberg, The Hallmarks of Cancer, pp 57-70, Copyright Elsevier (2000).
Evading apoptosis:
Tumor cells avoid apoptosis (programmed cell death) and expand in number1
Reference:
- 1.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.